Chandigarh, India, February 2025 – Anil Agrawal has been appointed as Chief Operating Officer (COO) at Ind-Swift Laboratories Ltd., bringing over 25 years of expertise in pharmaceutical operations, manufacturing, and strategic leadership. His deep experience in operational excellence, business transformation, and efficiency optimization will drive Ind-Swift’s growth and innovation in pharmaceutical formulations.
Prior to joining Ind-Swift Laboratories Ltd., Anil served as Head of Operations – Formulation at Alembic Pharmaceuticals Ltd., where he played a pivotal role in scaling production, process enhancement, and strategic partnerships. Before that, he was Senior Vice President – Operations at PAR Formulations, overseeing multi-site manufacturing and operational strategy. His tenure at Apnar Pharma Pvt. Ltd. as COO further strengthened his leadership in pharmaceutical plant management and regulatory compliance.
Earlier, Anil held senior leadership positions at Sun Pharmaceutical Industries Ltd., where he was responsible for formulation operations and business efficiency. At Zydus Cadila Healthcare Ltd., he served as Senior Vice President – Manufacturing Formulations, leading India’s largest pharmaceutical manufacturing sites. His career also includes key roles at Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, GlaxoSmithKline Pharmaceuticals Ltd., and Ranbaxy Laboratories Ltd., where he gained expertise in manufacturing operations, compliance, and large-scale production.
Anil holds a Pharmacy degree from Devi Ahilya Vishwavidyalaya, Indore, and has built a strong track record in pharmaceutical manufacturing, strategic business expansion, and innovation. His appointment at Ind-Swift Laboratories Ltd. is expected to enhance operational efficiencies, drive formulation business growth, and support the company’s long-term vision in the global pharmaceutical sector.
About Ind-Swift Laboratories Ltd.
Founded in 1995, Ind-Swift Laboratories Ltd. has grown into a leading pharmaceutical manufacturer, with world-class production facilities, a dedicated R&D center, and a strong regulatory framework. The company specializes in APIs, finished dosage forms, and contract manufacturing, catering to both regulated and emerging markets. Ind-Swift remains committed to innovation, global quality standards, and enhancing healthcare solutions worldwide.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
